Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 21:9:992388.
doi: 10.3389/fcvm.2022.992388. eCollection 2022.

Plasma desmosine for prediction of outcomes after acute myocardial infarction

Kashan Ali  1 , Muhammad Zubair Israr  2   3 , Leong L Ng  2   4 , Ify Mordi  1 , Chim C Lang  1 , Elena Kuzmanova  5 , Jeffrey T-J Huang  5 , Anna-Maria Choy  1
Affiliations

Plasma desmosine for prediction of outcomes after acute myocardial infarction

Kashan Ali et al. Front Cardiovasc Med. .

Abstract

Background: Elastin degradation is implicated in the pathology of vulnerable plaque. Recent studies show promising results for plasma desmosine (pDES), an elastin-specific degradation product, as a marker of cardiovascular disease (CVD) outcomes. The aim of this study was to investigate the potential role of pDES as a marker of clinical outcome in patients with acute myocardial infarction (AMI).

Materials and methods: In this case-control study, we studied 236 AMI patients: 79 patients who had death and/or myocardial infarction (MI) at 2 years, and 157 patients who did not have an event at 2 years. pDES was measured using a validated liquid chromatography-tandem mass spectrometry method. Association of pDES with adverse outcomes, and the incremental value of pDES to global registry of acute coronary events (GRACE) score for risk stratification was assessed.

Results: pDES levels were elevated in patients with the composite outcome of death/MI at 2 years (p = 0.002). Logistic regression analyses showed pDES to be associated with death/MI at 2 years [Odds ratio (OR) 5.99 (95% CI 1.81-19.86) p = 0.003]. pDES remained a significant predictor of death/MI at 2 years even after adjustment for age, sex, history of CVD, revascularisation, blood pressure, medications on discharge, Troponin I, and NT-proBNP levels.[OR 5.60 (95% CI 1.04-30.04) p = 0.044]. In another multivariable model including adjustment for eGFR, pDES was significantly associated with the composite outcome at 6 months, but not at 2 years follow up. DES was also able to reclassify risk stratification for death/MI at 6 months, when added to the GRACE risk model [Net Reclassification Index (NRI) 41.2 (95% CI 12.0-70.4) p = 0.006].

Conclusion: pDES concentrations predict clinical outcomes in patients with AMI, demonstrating its potential role as a prognostic marker in AMI.

Keywords: GRACE score; acute myocardial infarction; biomarkers; cardiovascular outcomes; plasma desmosine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Box plot showing plasma desmosine (pDES) concentrations according to no events vs. death/myocardial infarction (MI) at 2 years (p = 0.002 by Mann–Whitney U test).
FIGURE 2
FIGURE 2
Plasma desmosine (pDES) is a potential novel biomarker of acute myocardial infarction (AMI).
See this image and copyright information in PMC

References

    1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. (2020) 141:e139–596. 10.1161/CIR.0000000000000757 - DOI - PubMed
    1. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. (2020) 42:1289–367. 10.1093/eurheartj/ehab285 - DOI - PubMed
    1. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. (2000) 284:835–42. 10.1001/jama.284.7.835 - DOI - PubMed
    1. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the 6 months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. (2006) 333:1091. 10.1136/bmj.38985.646481.55 - DOI - PMC - PubMed
    1. Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J. (2014) 35:552–6. 10.1093/eurheartj/eht530 - DOI - PubMed